As it eyes new opportunities for its delivery technology, Tekmira Pharmaceuticals is exploring the potential of its lipid nanoparticles (LNPs) as carriers for messenger RNA therapeutics, the company's top official said last week.

Meanwhile, as it keeps it focus primarily on its core RNAi programs, Tekmira anticipates quickly moving a hepatitis B candidate into the clinic, with data available before the end of the year, President and CEO Mark Murray said during a conference call held last week to discuss Tekmira's financial results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.